Rationale Obesity is a leading public health problem worldwide. Multiple lines of evidence associate deficits in the brain reward circuit with obesity. Objective Whether alterations in brain reward sensitivity precede or are a consequence of obesity is unknown. This study aimed to investigate both innate and obesity-induced differences in the sensitivity to the effects of an indirect dopaminergic agonist. Methods Rats genetically prone to diet-induced obesity (DIO) and their counterpart diet-resistant (DR) were fed a chow diet, and their response to D-amphetamine on intracranial selfstimulation and food intake were assessed. The same variables were then evaluated after exposing the rats to a high-fat diet, after DIO rats selectively developed obesity. Finally, gene expression levels of dopamine receptors 1 and 2 as well as tyrosine hydroxylase were measured in reward-related brain regions.
Introduction
Obesity is an epidemic medical condition defined by the World Health Organization as a body mass index (BMI) ≥30 kg/m 2 . Obesity shows high comorbidity with a variety of diseases, raising both the economic impact of healthcare and the risk of mortality (Bray 2004; Lehnert et al. 2013) . Obesity is a polygenic disorder and results from the complex interaction with an obesogenic environment (Speakman 2004 ).
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* Pietro Cottone cottone@bu.edu In this context, a useful tool in preclinical research to study the interaction between genes and diet is represented by rats genetically prone to diet-induced obesity (DIO) and their dietresistant (DR) counterpart (Levin et al. 1997) . When fed a standard chow diet, DIO rats are lean; however, when exposed to a high-fat diet, they disproportionally gain weight and become obese, while DR remain lean Levin et al. 1997) . Therefore, the DIO/DR rodent model effectively mimics the polygenic, heritable differences in the vulnerability to diet-induced obesity observed in humans, allowing the study of pre-existing, predisposing factors leading to obesity (Cottone et al. 2007 ).
In addition to metabolic and homeostatic mechanisms, the brain reward system plays an equally important role in feeding. Indeed, the mesocorticolimbic dopaminergic pathway, which is activated in response to palatable food, has a major influence on feeding behavior.
The hypothesis that increased caloric intake and weight gain in obesity is driven by central mechanisms regulating reward is supported by evidence demonstrating that obese subjects show a deficit in the brain reward circuitry and a general hyposensitivity of the dopaminergic system (Johnson and Kenny 2010; South and Huang 2008; van de Giessen et al. 2014; Volkow et al. 2013b ). These deficits may, in turn, lead obese subjects to compensate by eating more palatable food, as observed in drug addiction (Guo et al. 2014; Melis et al. 2005) .
However, how exactly the brain reward system regulates food intake and body fatness is unclear. In particular, whether these alterations precede the development of obesity or are a consequence is unknown.
In this study, we investigated the effect of D-amphetamine on brain reward function using intracranial self-stimulation (ICSS), as well as on food intake and body weight change, in order to assess the responsiveness of the dopaminergic system of DIO and DR rats in pre-obesity and obesity states. Damphetamine was chosen as a pharmacological tool to study the sensitivity of the dopaminergic system due its dopaminereleasing properties and consequent elevations of extrasynaptic dopamine levels (Fleckenstein et al. 2007; Sulzer 2011) . Acute D-amphetamine administration lowers the threshold for electrical stimulation, indicating a potentiation of the rewarding properties of electrical brain stimulation (Esposito et al. 1980; Goodall and Carey 1975; Kornetsky and Esposito 1979) .
Human brain imaging studies have demonstrated that obese patients have decreased dopamine 2 receptor (D2R) occupancy in the dorsal striatum, which negatively correlates with the body mass index (Wang et al. 2001) . Alterations of the mesolimbic/mesocortical dopaminergic system have also been reported in environmental and genetic animal models of obesity (Geiger et al. 2009; Volkow et al. 2011; Vucetic and Reyes 2010) . For the above reasons, here we also analyzed the gene expression of the dopaminergic system components in several brain regions, including the nucleus accumbens (NAcc), the dorsal striatum (DS), the ventral tegmental area (VTA), the ventromedial hypothalamus (VMH), and the lateral hypothalamus (LH) of both chow-fed and high-fat-fed DIO and DR rats. VTA, NAcc, and DS were chosen because of their role in the rewarding and reinforcing properties of drugs and food (Kelley and Berridge 2002; Koob and Volkow 2010; Volkow et al. 2012) ; the LH and the VMH were chosen because of their role in the dopaminergic regulation of feeding behavior (Leibowitz 1975b; Mayer and Thomas 1967) .
Materials and methods

Subjects
Diet-induced obesity (DIO) and diet-resistant (DR) rats (n=44) were purchased from Taconic (Huston, NY) (Levin et al. 1997) . Rats were housed in a 12-h reverse light/dark cycle, AAALACapproved vivarium. DIO and DR rats were fed either ad libitum chow (corn-based Harlan Teklad LM-485 Diet 7012 Cottone et al. 2007 )) or ad libitum high-fat diet (D12266B Research Diets, New Brunswick, NJ) for 4 weeks, to allow DIO to develop obesity (Ricci and Levin 2003) . Procedures adhered to the NIH Guide for the Care and Use of Laboratory Animals and the Principles of Laboratory Animal Care and were approved by the Institutional Animal Care and Use Committee of Boston University. Additional information is provided in the online Supplementary Information file.
Drugs
D-amphetamine doses (0, 0.1, 0.5, and 1 mg/kg) were administered intraperitoneally (i.p.) 10 min before experiments, using a Latin square within-subject design (Esposito et al. 1980; Grilly and Loveland 2001) . Additional information is provided in the online Supplementary Information file.
Surgery for electrode implantation
Surgery for electrode implantation was performed as previously described (Dore et al. 2013; Iemolo et al. 2012; Kenny and Markou 2005; Schulteis et al. 1995) . DIO and DR rats were unilaterally implanted with a 0.125-mm-diameter bipolar stainless steel electrode (Plastics One, Roanoke, VA) in the medial forebrain bundle at the level of the lateral hypothalamus, using the following coordinates from bregma: AP −0.5 mm, ML ±1.7 mm, DV −9.7 mm from the skull, with the incisor bar 5.0 mm above the interaural line (Pellegrino et al. 1979) . Additional information is provided in the online Supplementary Information file.
Intracranial self-stimulation procedure ICSS took place in previously described operant test chambers (Med Associates Inc., St. Albans, VT) (Iemolo et al. 2012) , and the ICSS procedure performed as previously reported (Dore et al. 2013; Iemolo et al. 2012 ) (see Supplementary Information file). Reward thresholds were assessed using a rateindependent discrete-trial current intensity procedure (Esposito and Kornetsky 1977) . The brain reward threshold is the minimal current intensity able to produce a response that maintains self-stimulation (Markou and Koob 1991) .
Food intake and body weight measurements
Pre-weighed food was provided at dark-cycle onset, 10 min after drug administration, and food intake was recorded 2, 6, and 24 h later. Twenty-four-hour rat body weight change was calculated.
Quantitative RT-PCR
RNA extraction, retrotranscription, and real-time PCR were performed as previously described (Baiamonte et al. 2014; Cottone et al. 2012 ). Additional information is available in the online Supplementary Information file.
Fat pad and body composition analysis
After prolonged ad libitum feeding with chow diet or high-fat diet, DIO and DR rats were euthanized, and carcasses were transferred to the University of Alabama-Birmingham where the body composition analysis was carried out as previously described (Cottone et al. 2007 . Additional information is available in the online Supplementary Information file.
Statistical analysis
ICSS, food intake, and body weight change data were analyzed using mixed design two-way ANOVAs. Following a statistically significant overall effect and/or interaction, separate one-way ANOVAs were performed. Pairwise post-hoc were either Student's t test (to compare two groups) or Fisher's least significant difference (LSD) analysis (for all others), after confirming significant omnibus effect (p≤0.05). Additional information is available in the online Supplementary Information file.
Results
Effects of D-amphetamine on ICSS threshold in chow-fed DIO and DR rats Basal, spontaneous ICSS threshold did not differ between genotypes during a 4-day baseline period (Genotype: F[1, 14]= 1.38, n.s.; 4-day average, mean ± SEM: DIO 90.3 ± 10.2 μA, DR 107.7±13.7 μA, not shown). Figure 1 shows that D-amphetamine treatment significantly lowered the ICSS threshold in both chow-fed DIO and DR rats (Treatment: F[3, 42] =10.14, p≤0.001; Genotype*Treatment: F[3,42]=1.46, n.s.). Pairwise comparisons revealed that while in DIO rats only the highest dose of D-amphetamine significantly lowered the ICSS threshold, both the middle and the highest dose did in DR rats. The percent reduction following the 0.5 and 1 mg/kg doses, compared to vehicle, was in DIO 11 and 28 % and in DR rats 27 and 38 %. As shown in Fig. 1b , Damphetamine had no effect on the latency to respond (Friedman test: DIO χ 2 =4.47, n.s.; DR χ 2 =2.49, n.s.), a measure of locomotor activity.
Effects of D-amphetamine on food intake and body weight gain in chow-fed DIO and DR rats
Similarly to what previously reported by Ricci and Levin (2003) , the chow intake of DIO rats was slightly but significantly higher as compared to DR rats (DIO 99.3±3.1 kcal, DR 86.8±3.8 kcal; t(16)=2.56, p<0.05, mean±SEM).
As shown in Fig. 2a , D-amphetamine exerted an anorectic effect in both chow-fed DIO and DR rats. The two-way ANOVA revealed that D-amphetamine reduced 2-h food intake differentially in DIO and DR rats (Genotype*Treatment: 06, p≤0.0001) . Indeed, while in DIO rats only the highest dose of D-amphetamine was effective, both the middle and the highest were in DR rats. The percent reduction following the 0.5 and 1 mg/kg doses, compared to vehicle, was in DIO 4.3 and 36.3 % and in DR 37.6 and 75.8 %.
Although main effects of the genotype and drug treatment were detected by the two-way ANOVA on the 6-h measures (Treatment: F[3, 48] Fig. 3 , one-way ANOVAs on individual genotypes revealed that Damphetamine administration lowered the ICSS threshold dose-dependently in DR rats, while it had no effect in obese DIO rats (DR Treatment: F[3, 18] =15.65, p≤ 0.001; DIO Treatment: F[3,18]=1.53, n.s.). Pairwise comparisons showed that in DR rats, all three doses tested significantly reduced the ICSS threshold. The percent reduction following the 0.5 and 1 mg/kg doses, compared to vehicle, was in DIO 12 and 19 % and in DR 31 and 32 %. While a linear contrast analyses did not show a significant Genotype×Treatment interaction under chow conditions (F(1,14)=0.18; n.s.), this was instead statistically significant under high-fat diet (F(1,12)=5.29; p<0.05), confirming the concept that differences in the response to the psychostimulants between genotypes became much more evident after exposure to high-fat food. As shown in Fig. 3b , the ICSS response latency was unaffected by drug administration (Friedman test: DIO χ 2 = 3.86, n.s.; DR χ 2 =3.86, n.s.). Effects of D-amphetamine on food intake and body weight gain in high-fat-fed DIO and DR rats
The high-fat food intake did not differ between genotypes (DIO 101.9±4.4 kcal, DR 89.7±8.0 kcal; t(16)=1.42, n.s.), consistent with previous reports Madsen et al. 2010) .
As shown in Fig. 4 , the effects of D-amphetamine administration in high-fat diet fed DIO and DR rats on food intake were more profound compared to chow (Fig. 2) . The two-way ANOVAs revealed that D-amphetamine administration exerted a significant effect at all the time points (Fig. 4a 2 entire 24-h period at the middle and highest doses tested. The lowest dose significantly reduced food intake in both genotypes only at the 2-h time point.
As shown in Fig. 4d, D Gene expression in chow or high-fat-fed DIO and DR rats As shown in Fig. 5 , lean chow-fed DIO rats showed higher D1R and D2R mRNA levels, compared to chow-fed DR rats, in the VTA and in the DS, but not in the NAcc (VTA D1R: t (15) Moreover, in the VTA chow-fed DIO rats showed higher mRNA levels of the biosynthetic enzyme tyrosine hydroxylase (TH) compared to the DR rats (t(16)=2.48, p≤0.03).
Interestingly, obese DIO rats had lower D1R mRNA level, compared to the lean high-fat-fed DR rats in the VTA (t(9)= 2.44, p≤0.03) and in the NAcc (t(10)=5.10, p≤0.0005), but not in the DS (t(12)=1.26 n.s.). High-fat-fed obese DIO rats did not differ from their lean counterpart in either D2R or TH mRNA levels in any brain area (VTA D2R: t(11)=0.01, n.s.; DS D2R: t(11)=0.65, n.s.; NAcc D2R: t(10)=1.65, n.s.; VTA TH: t(10)=0.38, n.s.).
Body composition analysis
DIO rats were significantly smaller upon arrival compared to DR rats, despite being of the exact same age (mean±SEM: DIO 266±5.0 g, DR 289±8.6 g; t(18)=2.28, p≤0.05; not shown). However, DIO rats gained weight faster compared to DR rats over a 2-month period on chow (Genotype*Time: (NAcc), and in the dorsal striatum (DS) in chow-fed (a, b, and c) and highfat diet-fed (d, e, and f) DIO and DR rats (n=7-9/genotype). Data represent mean±SEM expressed as percent of DR rats. *p≤ 0.05, **p≤0.01, **p≤0.001 vs. DR rats significantly differ at sacrifice (mean±SEM: DIO 357±4.6 g, DR 370±10.2 g; t(18)=1.16, n.s.).
As previously shown (Cottone et al. 2007 ), chow-fed DIO rats had smaller whole carcass adiposity, measured as either in grams or percentages of body weight, compared to DR. Fat pad analysis revealed that DIO subcutaneous fat pads were significantly smaller compared to DR rats (t(18)=4.05, p≤0.001, Table 1). Inguinal, mesenteric, and the brown fat pads from chowfed DIO rats tended to be smaller compared to DR rats (t(18)> 1.89, p≤0.07). Thus, the adiposity values in both genotypes were consistent with a lean state (Cottone et al. 2007) .
During the four weeks of exposure on high-fat diet, DIO rats disproportionally gained more weight compared to DR (Genotype*Time: F[1,16]=22.49, p≤0.001; Genotype: F[1, 16]=14.57, p≤0.001) (4-week body weight gain, mean± SEM: DIO 101.8±6.3 g, DR 54.19±8.0 g; t(16)=4.05, p≤ 0.001; not shown). At the time of sacrifice, the high-fat-fed DIO rats were significantly heavier than high-fat-fed DR (mean±SEM: DIO 804±32.5 g, DR 626±32.5 g; t(17)= 3.86, p≤0.001; not shown).
As shown in Table 1 , the fat pad analysis revealed that all the DIO adiposity parameters analyzed were significantly higher when compared to DR (t(16)=2.47, p≤0.03) consistent with the development of the adipose state (Levin 1999; Levin et al. 1997 ).
Discussion
The results of the present study were as follows: (I) before the onset of obesity, DIO rats show an innate decreased sensitivity to the effects of D-amphetamine on ICSS threshold and feeding, as compared to DR rats; (II) in a diet-induced obesity state, DIO rats show insensitivity to the D-amphetamine effect on ICSS but show equal sensitivity to its anorectic effect, compared to lean DR rats; and (III) DIO rats show differences in gene expression of components of the dopaminergic system compared to DR rats, both before and after the development of obesity.
By releasing dopamine and inhibiting uptake, the indirect agonist D-amphetamine potentiates the rewarding properties of electrical brain stimulation, observed as a decrease in the ICSS threshold (Esposito et al. 1980; Goodall and Carey 1975) . In this study, we showed that chow-fed DIO rats, in a pre-obesity state, exhibit an innate reduced sensitivity to the effects of D-amphetamine on ICSS threshold, as compared to DR rats. Specifically, D-amphetamine was less potent in lean DIO rats than in DR. Therefore, these results reveal that a deficit in the brain reward function happens before the onset of obesity in DIO rats, being pre-existing and independent from the exposure to energy-dense food. Thus, an innate hypofunctional dopaminergic brain reward system could be a contributing factor in the development of obesity. In support of this hypothesis, brain imaging studies in obese patients reported decreased D2R density in striatal brain regions that was negatively correlated with the BMI (Guo et al. 2014; Wang et al. 2001) , and a polymorphism of Taq I A1 allele of D2R has been associated with obesity in humans (Blum et al. 1996) . However, while human studies present limitations in their ability to detect vulnerability factors which can predict the onset of diseases (O'Brien and Gardner 2005) , preclinical animal studies allow a greater control of the experimental variables (Levin et al. 1997; Sabino et al. 2009; VelazquezSanchez et al. 2014) . Previous reports have suggested that hyposensitivity of the dopaminergic system is associated with obesity also in animal models. Multiple studies have shown in obese animals a lower brain reward function, decreased levels of components of the dopaminergic machinery in limbic areas of the brain, and/or a decreased responsiveness to dopamine receptor ligands (Alsio et al. 2010; Davis et al. 2008; Geiger et al. 2009; Johnson and Kenny 2010; Koyama et al. 2014; South and Huang 2008) . Therefore, the difference between lean DIO and DR rats in ICSS threshold observed following D-amphetamine treatment provides further valuable information about which phenotypes may represent risk factors for the development of obesity, suggesting a causal relationship between the brain reward deficit and the predisposition to obesity.
In this study, we observed that the resistance to the rewardenhancing effects of D-amphetamine in DIO rats was exacerbated following exposure to the high-fat diet, when rats were in an obvious obesity state, as demonstrated by the carcass analysis. While all doses lowered ICSS threshold in lean high-fat-fed DR rats, obese DIO rats did not respond to any. Based on these data, we can conclude that the decreased reward sensitivity, hypothesized as being a contributing factor for the development of obesity, results both from predisposing heritable factors and the interaction with high-energy foods (Johnson and Kenny 2010; Wang et al. 2001) . These findings further corroborate the hypothesis that obesity is a polygenic disorder resulting from the interaction between an innate vulnerable phenotype and the increased availability of energydense food (Speliotes et al. 2010; Volkow et al. 2013a ). The reduced responsivity of DIO to the potentiating effects of Damphetamine on the brain reward system function but the absence of spontaneous decreases in brain reward function in DIO rats suggests that the reward deficiency in DIO rats becomes evident only after the system is challenged by a dopaminergic agent, and this result is in conflict with previous observations by Johnson and Kenny (2010) , who demonstrated that obese rats overeating a cafeteria diet show elevated ICSS threshold compared to rats fed chow. Yet, a direct comparison between the two studies is difficult as that study was performed in outbred Wistar rats, while our study was performed in inbred Sprague-Dawley. Our study is in agreement with reports showing a lower response of both obesity-prone rats as well as Sprague-Dawley rats on a cafeteria-style diet to D-amphetamine-induced dopamine release in the NAcc (Geiger et al. 2008 (Geiger et al. , 2009 ).
The possible mechanism responsible for the reduced sensitivity to the reward-potentiating effects of the dopaminergic agent D-amphetamine may involve leptin. Dopaminergic neurons of the VTA were shown to be responsive to leptin and the diminished locomotor response to amphetamine of ob/ob mice to be reversed by leptin (Fulton et al. 2006a) . Therefore, it can be hypothesized that the reduced dopaminergic sensitivity in DIO rats may be due to a defective central leptin signaling, which is present already before obesity onset.
It is noteworthy to mention that specific areas of the LH, a region where the electrode was placed, may be differentially sensitive to diets and feeding signals compared to others (Fulton et al. 2006a ); indeed, the reward produced by stimulating the LH is affected by food restriction and body weight, and it is attenuated by leptin (Fulton et al. 2006b; Shizgal et al. 2001) . Therefore, slightly different histological location on the tip of the electrode could account for the variability of neuronal excitation along the medial forebrain bundle.
Similarly to what we observed in the ICSS, D-amphetamine decreased feeding less potently in lean, chow-fed DIO rats when compared to DR. The lower potency in the anorectic effect in DIO rats is not surprising. Indeed, resistance to multiple anorexigens was observed before obesity onset in obesity-prone rats (Irani et al. 2007; Levin et al. 2003 Levin et al. , 2004 . DIO rats show central insulin resistance and lower anorectic response to leptin even before obesity (Clegg et al. 2005; Levin et al. 2004 ). In addition, lean chow-fed DIO rats show decreased anorexia by CRF2 agonist stimulation compared to DR rats (Cottone et al. 2007) . Another phenotype existing prior to the development of obesity is represented by profound differences in meal pattern in lean chow-fed DIO, compared to DR, rats; DIO rats show signs of a pre-existing deficit in the maintenance of post-meal satiety which resembles human Bsnacking^behavior (Cottone et al. 2007 ). Interestingly, snacking behavior, a phenotype typically observed in children, represents a risk factor for adult obesity (Francis et al. 2003) . Therefore, dopamine hyposensitivity, together with altered metabolic factors, may play a role in the development of obesity in DIO rats.
DIO and DR rats have previously been compared for spontaneous motor activity in an open field as well as for spontaneous physical activity in the presence of a running wheel, and in both cases, no differences between genotypes were found while on chow diet (Levin 1991; Levin and Dunn-Meynell 2006) . Furthermore, exposure to high-fat diet reduced running activity in equal degree in DIO and DR rats. These results suggest that the DIO rats's vulnerability to obesity and their hyposensitive dopaminergic system are likely not associated with altered physical activity.
D-amphetamine treatment decreased high-fat diet intake of DIO and DR rats similarly. Interestingly, drug treatment was more potent in reducing body weight in the obese DIO rats as compared to lean DR. These findings are in line with previous observations obtained in a different model of obesity, which show that genetically obese Zucker rats are more sensitive to D-amphetamine anorexic effect than lean rats (Grinker et al. 1980 ). An interesting observation is that the anorectic effect of D-amphetamine treatment was more potent, efficient, and long-lasting in both DIO and DR rats under a high-fat feeding regimen compared to when on standard chow diet. Since previous studies have shown a lack of interaction between the anorectic properties of amphetamine and diet palatability/energy density (Wellman et al. 1982) , we hypothesize that the long-term exposure to the high-fat diet may have induced neuroadaptations in the dopaminergic system, which were responsible for the sensitized anorectic effect to D-amphetamine observed here. In support of this hypothesis, previous reports showed in baboons that repeated access to candies increases sensitivity to the effects of Damphetamine on the intake of both candies and regular food (Foltin 2011) .
D-amphetamine is believed to exert its anorectic action by potentiating dopaminergic transmission in the hypothalamus, where it plays an important role in the regulation of food intake (Leibowitz 1975a; Vucetic and Reyes 2010) . In addition, a role for central noradrenergic systems in the anorectic effects of D-amphetamine has been proposed (Ahlskog 1974; Leibowitz 1975b; Sahakian et al. 1983) . Therefore, our results reveal that the effects of Damphetamine on ICSS and feeding are dissociable in the context of obesity. While the development of obesity exacerbated the hyposensitivity to the rewarding effects of D-amphetamine, therefore enhancing differences between genotypes, on the other hand, the exposure to the high-fat diet increased the drug's anorectic properties.
In this study, quantitative PCR (qPCR) showed that lean, chow-fed DIO rats showed high levels of D1R and D2R mRNA in both the DS and the VTA as compared to chowfed DR rats. In addition, gene expression of TH was higher in lean DIO rats vs. DR. These molecular data are not necessarily in contrast with the pharmacological data as they can be interpreted as compensatory responses to counterbalance the decreased availability of dopamine. qPCR results showed that under chow conditions, the VTA DA synthetic enzyme, TH, was increased in DIO rats, compared to DR, suggesting an upregulated rather than down-regulated system as instead suggested by the behavioral experiments. While we cannot completely rule out the possibility that the mesolimbic dopaminergic system is up-regulated in DIO rats, it can also be hypothesized that the increase in TH is a compensatory response to the functional downstream hyposensitivity of the dopaminergic system (Volkow et al. 2008 ). Geiger et al. reported lower TH mRNA and protein expression in VTA primary neuronal cultures obtained by chow-fed DIO rats compared to cells derived from chow-fed DR rats (Geiger et al. 2008) . However, differences in the sample source and processing could obviously account for this discrepancy. Notably, differences in D1R, D2R, and TH gene expression observed in pre-obesity were not observed in obese DIO rats. The selectivity of these effects is in line with evidence showing that certain altered features are observed in lean, obesity-prone rats but normalize following development of obesity (e.g., NPY and alpha-2 adrenoreceptors expressions and norepinephrine turnover) (Levin 1999; Levin and Dunn-Meynell 2000) . This phenomenon is believed to represent a neuroadaptative mechanism relevant for the defense of adiposity and body weight (Levin 1999) . Therefore, neuroadaptations occurring after prolonged exposure to high-fat diet might also explain why D-amphetamine retained its anorectic effect during high-fat food intake experiment in both DIO and DR rats.
In high-fat-fed DIO rats, after obesity was fully developed, we found significantly lower D1R gene expression levels compared to high-fat-fed DR rats, in both the NAcc and the VTA. Our results confirm previous observations by Sharma and Fulton (2012) who reported decreased D1R protein expression in the NAcc of high-fat-fed DIO mice as compared to low-fat-fed controls. Our results are also in agreement with those of Vucetic, showing reduced D1R in the VTA and the NAcc of obese mice (Vucetic et al. 2012; Vucetic and Reyes 2010) . Based on the role that the mesolimbic D1R plays in mediating the effects of ICSS (Ikemoto and Panksepp 1999; Markou and Koob 1992; Steinberg et al. 2014) , it can be hypothesized that the hyposensitivity of obese DIO rats to the reward-enhancing effect of D-amphetamine be due to lower D1R expression.
Obese DIO rats did not show reduced D2R mRNA expression in the DS compared to high-fat-fed DR rats. This observation contrasts some evidence collected in obese patients and rodents (Wang et al. 2001) . A noticeable discrepancy can be found in the literature in relation to the expression of D2R in animal models of obesity; for instance, Sharma and Fulton (2012) did not find differences in the expression of D2R in the DS, and two other studies have reported elevated D2R expression level in the DS of obesity-prone animals (Alsio et al. 2010; South and Huang 2008) . Another important factor may be represented by the relative contribution of the two isoforms of D2R, short and long (Geiger et al. 2008; Johnson and Kenny 2010) . Indeed, Johnson and Kenny (2010) reported that rats fed a cafeteria diet show a lower striatal protein expression of the mature and fully glycosylated (70 kDa) membrane-bound D2R isoform compared to chow-fed rats, while no differences in the expression of either the unglycosylated immature (D2S,~39 kDa) or the intermediate glycosylated cytoplasmic (D2L,~51 kDa) forms of D2R were found. Another difference with previous reports is represented by the fact that differences in the expression of the receptor protein were assessed, while the present study investigated mRNA levels. Therefore, further studies are needed in order to better elucidate the role of D2R in the mesolimbic system in obesity.
In contrast, no differences in the gene expression levels of dopaminergic receptors were found in either LH or VMH between the two genotypes on chow or high-fat diet. Therefore, the differential anorectic effect of D-amphetamine on chow intake in DIO and DR rats may be not related to hypothalamic levels of these receptors.
One limitation of the present study is that the samples from either chow-fed or high-fat-fed DIO/DR rats were analyzed in separate qPCR experiments, therefore making a direct comparison between expression levels under chow and high-fat condition not possible. Even though qPCR is considered a technique which provides absolute measures of gene expression, measurements are deeply affected by inter-assay differences. Hence, while the present mRNA data provide important information regarding putative difference between genotypes under either feeding conditions, they do not allow drawing conclusions about the effect that the high-fat diet exposure had on gene expression in each genotype.
In conclusion, our data suggests that obesity-prone rats show a heritable, pre-existing deficit of the brain reward system, which is exacerbated by the exposure to a high-fat diet and the development of obesity. A better understanding of preexisting dysfunctions in the dopaminergic brain reward system and its interaction with energy-dense food gives new insights into the disease pathogenesis and may yield new therapeutic opportunities.
